Hematology Frontier

The 66th Annual Meeting of the American Society of Hematology (ASH) took place from December 7–10, 2024, in San Diego, USA. As one of the largest and most prestigious international conferences in the field of hematology, ASH highlighted groundbreaking advancements and new drug development data, showcasing the highest levels of academic research globally. Platelet delay or engraftment failure is a serious complication of allogeneic hematopoietic stem cell transplantation (allo-HSCT). Strategies to accelerate platelet engraftment remain a critical clinical challenge. At this year’s ASH meeting, Dr. Erlie Jiang and his team from the Institute of Hematology & Blood Diseases Hospital (Chinese Academy of Medical Sciences) presented findings from their study (Abstract #266) investigating the effects of elevated recombinant human thrombopoietin (rhTPO) dosing on platelet engraftment in allo-HSCT. Hematology Frontier interviewed Prof. Jiang to explore the research findings and their implications.

Acute myeloid leukemia (AML) remains a major clinical challenge due to its high heterogeneity. While CAR-T cell therapy has shown tremendous success in treating various hematologic malignancies, its application in AML is still in its infancy, necessitating further research and exploration. At the 2024 American Society of Hematology (ASH) Annual Meeting, held from December 7–10, Dr. Mingfeng Zhao from Tianjin First Central Hospital presented groundbreaking findings on a novel iCAR-T therapy for AML, offering renewed hope for patients. Hematology Frontier had the privilege of inviting Prof. Zhao to discuss this study and share insights on his team’s future research plans.

From December 7–10, 2024, the 66th Annual Meeting of the American Society of Hematology (ASH) was held in San Diego, bringing together global experts and scholars in hematology for an in-depth exploration and exchange of the latest research progress in the field. Among the highlights of this year’s conference were three oral presentations (Oral 94, 238, 367) focusing on CAR-T cell therapy for lymphoma. These studies showcased the latest advancements in CAR-T therapy from three perspectives: enhancing accessibility, optimizing efficacy, and addressing resistance mechanisms. Hematology Frontier invited Dr. Wenbin Qian from The Second Affiliated Hospital of Zhejiang University School of Medicine to provide an in-depth analysis of these three studies, offering valuable guidance and insights for clinical practice.

The 66th American Society of Hematology (ASH) Annual Meeting, held from December 7 to 10, 2024, in San Diego, showcased cutting-edge advancements in hematology. Among the highlights was a study led by Dr. Peihua Lu from the Beijing Lu Daopei Hematology Hospital, presenting Phase I clinical trial results on CD7 CAR-T cell therapy for relapsed or refractory peripheral T-cell lymphoma (R/R PTCL). In this feature, Hematology Frontier invited Professor Lu to share insights into the study's findings, the strategy for expanding CD7 CAR-T indications, and future research plans.

From December 7–10, 2024, the 66th Annual Meeting of the American Society of Hematology (ASH) was held in San Diego, bringing together global experts and scholars in hematology for an in-depth exploration and exchange of the latest research progress in the field. At this conference, two studies by Dr. Sizhou Feng's team from the Institute of Hematology & Blood Diseases Hospital (Chinese Academy of Medical Sciences) were included for poster presentation (P2127, P2828). "Hematology Frontier" specially invited Dr. Feng to share the research findings and their clinical significance with colleagues at the ASH venue as soon as possible.

From December 7–10, 2024, the 66th Annual Meeting of the American Society of Hematology (ASH) convened in San Diego, USA, drawing global experts and scholars to discuss the latest advancements in hematology. In recent years, increasing insights into the pathogenesis of immune thrombocytopenia (ITP) have paved the way for innovative treatment strategies, among which SYK inhibitors have garnered significant attention due to their unique mechanisms of action. At this year’s ASH conference, Dr. Hu Zhou from Henan Cancer Hospital shared his team’s latest findings (711) on this front, offering fresh perspectives for future therapeutic strategies. Hematology Frontier invited Dr. Zhou for an in-depth discussion on his study and its clinical significance.

From December 7–10, 2024, the 66th Annual Meeting of the American Society of Hematology (ASH) was held in San Diego, USA, bringing together global experts and scholars in hematology to discuss the latest research developments. At this year’s conference, Dr. Qingqing Cai’s team from Sun Yat-sen University Cancer Center presented two research posters (P3047, P4450), offering novel perspectives and important insights into immunotherapy combinations for relapsed/refractory lymphoma. Hematology Frontier invited Dr. Cai to share the clinical significance and key findings of her team’s research.

From December 7–10, 2024, the 66th Annual Meeting of the American Society of Hematology (ASH) convened in San Diego, USA, bringing together global experts and scholars to discuss cutting-edge advancements in hematology. At this prestigious event, Dr. Wei Xu’s team from The First Affiliated Hospital of Nanjing Medical University presented their groundbreaking research titled Clinical Implications of CSF-Ctdna Positivity in Newly Diagnosed Diffuse Large B Cell Lymphoma in a Large Cohort. This study, selected for oral presentation (O576), not only deepens our understanding of CNS involvement in DLBCL but also offers innovative perspectives for clinical management and treatment strategies. Hematology Frontier invited Dr. Xu to share insights into the significance of CSF-ctDNA testing, its potential role in future DLBCL clinical practice, and its far-reaching impact on patient treatment strategies.

From December 7–10, 2024, the 66th Annual Meeting of the American Society of Hematology (ASH) convened in San Diego, USA, bringing together global experts and scholars to discuss cutting-edge advancements in hematology. At this year’s conference, Dr. Yang Liang’s team from Sun Yat-sen University Cancer Center presented groundbreaking research on the mechanisms of clonal hematopoiesis (O192). The findings revealed a novel connection between DNMT3A mutations and immune microenvironment dysregulation, offering a fresh perspective on the origins and progression of clonal hematopoiesis. Hematology Frontier invited Dr. Liang for an in-depth discussion on the clinical significance of this research and its potential future applications.

From December 7–10, 2024, the 66th Annual Meeting of the American Society of Hematology (ASH) took place in San Diego, USA, gathering leading global experts to discuss the latest advancements in hematology. At this year’s conference, Dr. Haiwen Huang’s team from The First Affiliated Hospital of Soochow University presented three impactful studies through poster sessions (P1676, P3113, P4442). Hematology Frontier invited Professor Huang to share their insights and the clinical implications of these studies directly from the ASH venue.